The use of antipsychotics among people treated with medications for dementia in residential aged care facilities.

Shin, H-Y; Gadzhanova, S; Roughead, EE; Ward, MB; Pont, LG

The use of antipsychotics among people treated with medications for dementia in residential aged care facilities.

Shin, H-Y Gadzhanova, S Roughead, EE Ward, MB Pont, LG

Permalink

Publisher:: CAMBRIDGE UNIV PRESS
Publication Type:: Journal Article
Citation:: International psychogeriatrics, 2016, 28, (6), pp. 977-982
Issue Date:: 2016-06

Closed Access

	Filename	Description	Size
	2016_Hee-Young_Int J Psychogeriatrics.pdf	Published version	224.26 kB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Shin, H-Y
dc.contributor.author	Gadzhanova, S
dc.contributor.author	Roughead, EE
dc.contributor.author	Ward, MB
dc.contributor.author	Pont, LG
dc.date.accessioned	2022-01-25T01:27:29Z
dc.date.available	2022-01-25T01:27:29Z
dc.date.issued	2016-06
dc.identifier.citation	International psychogeriatrics, 2016, 28, (6), pp. 977-982
dc.identifier.issn	1041-6102
dc.identifier.issn	1741-203X
dc.identifier.uri	http://hdl.handle.net/10453/153537
dc.description.abstract	Antipsychotic agents have limited efficacy for Behavioral and Psychological Symptoms of Dementia (BPSD) and there are concerns about their safety. Despite this, they are frequently used for the management of BPSD. This study aimed to assess the use of antipsychotics among people on anti-dementia medicines in Australian residential aged care facilities.Data were obtained from an individual patient unit dose packaging database covering 40 residential aged care facilities in New South Wales, Australia. Residents supplied an anti-dementia medicine between July 2008 and June 2013 were included. Prevalence of concurrent antipsychotic use was established. Incident antipsychotic users between January 2009 and December 2011 were identified. We examined initial antipsychotic dose, maximum titrated doses, type and duration of antipsychotic use, and compared use with Australian guidelines.There were 291 residents treated with anti-dementia medicines, 129 (44%) of whom received antipsychotics concomitantly with an anti-dementia medicine. Among the 59 incident antipsychotic users, risperidone (73%) was the most commonly used antipsychotic agent. Amongst the risperidone initiators, 43% of patients had initial doses greater than 0.5 mg/day and 6% of patients exceeded 2.0 mg/day for their maximum dose. 53% of concomitant users received daily treatment for greater than six months.Our study using records of individual patient unit dose supply, which represents the intended medication consumption schedule, shows high rates of concurrent use of antipsychotics and anti-dementia medicines and long durations of use. The use of antipsychotics in patients with dementia needs to be carefully monitored to improve patient outcomes.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	CAMBRIDGE UNIV PRESS
dc.relation.ispartof	International psychogeriatrics
dc.relation.isbasedon	10.1017/s1041610215002434
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Geriatrics
dc.subject.mesh	Aged
dc.subject.mesh	Antipsychotic Agents
dc.subject.mesh	Assisted Living Facilities
dc.subject.mesh	Australia
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Dementia
dc.subject.mesh	Drug Administration Schedule
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Incidence
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	New South Wales
dc.subject.mesh	Prevalence
dc.subject.mesh	Residential Facilities
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Risperidone
dc.subject.mesh	Humans
dc.subject.mesh	Dementia
dc.subject.mesh	Risperidone
dc.subject.mesh	Antipsychotic Agents
dc.subject.mesh	Drug Administration Schedule
dc.subject.mesh	Incidence
dc.subject.mesh	Prevalence
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Residential Facilities
dc.subject.mesh	Assisted Living Facilities
dc.subject.mesh	Australia
dc.subject.mesh	New South Wales
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.title	The use of antipsychotics among people treated with medications for dementia in residential aged care facilities.
dc.type	Journal Article
utslib.citation.volume	28
utslib.location.activity	England
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-01-25T01:27:27Z
pubs.issue	6
pubs.publication-status	Published
pubs.volume	28
utslib.citation.issue	6

Abstract:

Antipsychotic agents have limited efficacy for Behavioral and Psychological Symptoms of Dementia (BPSD) and there are concerns about their safety. Despite this, they are frequently used for the management of BPSD. This study aimed to assess the use of antipsychotics among people on anti-dementia medicines in Australian residential aged care facilities.Data were obtained from an individual patient unit dose packaging database covering 40 residential aged care facilities in New South Wales, Australia. Residents supplied an anti-dementia medicine between July 2008 and June 2013 were included. Prevalence of concurrent antipsychotic use was established. Incident antipsychotic users between January 2009 and December 2011 were identified. We examined initial antipsychotic dose, maximum titrated doses, type and duration of antipsychotic use, and compared use with Australian guidelines.There were 291 residents treated with anti-dementia medicines, 129 (44%) of whom received antipsychotics concomitantly with an anti-dementia medicine. Among the 59 incident antipsychotic users, risperidone (73%) was the most commonly used antipsychotic agent. Amongst the risperidone initiators, 43% of patients had initial doses greater than 0.5 mg/day and 6% of patients exceeded 2.0 mg/day for their maximum dose. 53% of concomitant users received daily treatment for greater than six months.Our study using records of individual patient unit dose supply, which represents the intended medication consumption schedule, shows high rates of concurrent use of antipsychotics and anti-dementia medicines and long durations of use. The use of antipsychotics in patients with dementia needs to be carefully monitored to improve patient outcomes.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/153537